



December 18, 2023

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.,
Exchange Plaza,
Plot No. C-1, Block G,
Bandra Kurla Complex,
Bandra (E)
Mumbai – 400051

Symbol: UNIHEALTH

Ref: Email dated December 14, 2023 – Clarification for financial results.

Dear Sir/Madam,

We refer to your email dated December 14, 2023, with reference to the captioned subject regarding deficiency observed in financial results submitted for the half year ended September 30, 2023 with respect to Segment details not submitted.

In this regard, we state that the Company operates in a single business segment i.e. healthcare segment and therefore, has only one reportable segment in accordance with applicable accounting standards. The same has been intimated in the XBRL format submitted to you on November 08, 2023 as required under the SEBI Listing Regulations for standalone and consolidated financial results, reports of which are attached herewith for your reference.

We hope this clarifies.

Thanking you,

Yours faithfully,

For Unihealth Consultancy Limited
(Formerly Unihealth Consultancy Private Limited)

PRAJAKTA
SURESH BHOR

Digitally signed by
PRAJAKTA SURESH
BHOR
Date: 2023.12.18
11:48:34 +05'30'

Prajakta Bhore
Company Secretary/ Compliance Officer



Encl: As above

UniHealth Consultancy Limited

(Formerly known as Unihealth Consultancy Private Limited)

Registered Office : H-13/14, Everest, 156, Tardeo Road, Mumbai - 400 034, Maharashtra, India.

+91 22 2354 4625 / 27 info@unihealthonline.com www.unihealthonline.com | www.umchospitals.com

CIN No.: U85100MH2010PLC200491

Scrip code	
Scrip code	
NSE Symbol	UNIHEALTH
MSEI Symbol	NA
ISIN	INE0PRF01011
Name of company	Unihealth Consultancy Limited
Result Type	Main Format
Type of company	SME
Class of security	Equity
Date of start of financial year	01-04-2023
Date of end of financial year	31-03-2024
Date of board meeting when results were approved	08-11-2023
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	31-10-2023
Description of presentation currency	INR
Level of rounding used in financial results	Lakhs
Reporting Quarter	Half yearly
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited	Unaudited
Segment Reporting	Single segment
Description of single segment	Healthcare
Start date and time of board meeting	08-11-2023 11:00
End date and time of board meeting	08-11-2023 12:30
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable

Financial Results – Other than Bank			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2023	01-04-2023
B	Date of end of reporting period	30-09-2023	30-09-2023
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Revenue From Operations		
	Revenue from operations	91.91	91.91
	Other income	95.92	95.92
	Total Revenue	187.83	187.83
2	Expenses		
(a)	Cost of materials consumed	0	0

(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0	0
(d)	Employee benefit expense	59.02	59.02
(e)	Finance costs	31.87	31.87
(f)	Depreciation and amortisation expense	3.81	3.81
(g)	Other Expenses		
1	Other Expenses	34.51	34.51
2	Miscellaneous Expenses	29.91	29.91
	Total other expenses	64.42	64.42
	Total expenses	159.12	159.12

Financial Results – Other than Bank			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2023	01-04-2023
B	Date of end of reporting period	30-09-2023	30-09-2023
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
3	Profit before exceptional and extraordinary items and tax	28.71	28.71
4	Exceptional items	0	0
5	Profit before extraordinary items and tax	28.71	28.71
6	Extraordinary items	0	0
7	Profit before tax	28.71	28.71
	Current tax	0	0
	Deferred tax	-20.9	-20.9
	Total tax expenses	-20.9	-20.9
9	Net Profit Loss for the period from continuing operations	49.61	49.61
10	Profit (loss) from discontinuing operations before tax	0	0
11	Tax expense of discontinuing operations	0	0
12	Net profit (loss) from discontinuing operation after tax	0	0
13	Profit (loss) for period before minority interest	49.61	49.61
16	Net profit (Loss) for the period	49.61	49.61

Financial Results – Other than Bank			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2023	01-04-2023
B	Date of end of reporting period	30-09-2023	30-09-2023
C	Whether results are audited or unaudited	Unaudited	Unaudited

D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
17	Details of equity share capital		
	Paid-up equity share capital	1540	1540
	Face value of equity share capital	10	10
17	Details of debt securities		
	Basic earnings (loss) per share from continuing and discontinued operations	0.43	0.43
20	Debt equity ratio		
21	Debt service coverage ratio	0.06	0.06
22	Interest service coverage ratio	1.9	1.9

Statement of Asset and Liabilities		
	Particulars	Half year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2023
	Date of end of reporting period	30-09-2023
	Whether results are audited or unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone
	Equity and liabilities	
1	Shareholders' funds	
	Share capital	1540
	Reserves and surplus	4665.56
	Money received against share warrants	
	Total shareholders' funds	6205.56
2	Share application money pending allotment	0
3	Deferred government grants	0
4	Minority interest	
5	Non-current liabilities	
	Long-term borrowings	602.57
	Deferred tax liabilities (net)	
	Foreign currency monetary item translation difference liability account	
	Other long-term liabilities	
	Long-term provisions	0
	Total non-current liabilities	602.57
6	Current liabilities	
	Short-term borrowings	11.22
	Trade Payables	
	(A) Total outstanding dues of micro enterprises and small enterprises	5.95
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	15.7
	Other current liabilities	734.93
	Short-term provisions	21.5
	Total current liabilities	789.3
	Total equity and liabilities	7597.43

	Assets	
1	Non-current assets	
(i)	Fixed assets	
	Tangible assets	138.14
	Producing properties	
	Intangible assets	0.31
	Preproducing properties	
	Tangible assets capital work-in-progress	
	Intangible assets under development or work-in-progress	
	Total fixed assets	138.45

Statement of Asset and Liabilities		
Particulars		Half year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2023
Date of end of reporting period		30-09-2023
Whether results are audited or unaudited		Unaudited
Nature of report standalone or consolidated		Standalone
(ii)	Non-current investments	634.2
(v)	Deferred tax assets (net)	43.22
(vi)	Foreign currency monetary item translation difference asset account	
(vii)	Long-term loans and advances	1486.02
(viii)	Other non-current assets	130.22
	Total non-current assets	2432.11
Current assets		
	Current investments	0
	Inventories	0
	Trade receivables	83.9
	Cash and cash equivalents	0
	Bank balance other than cash and cash equivalents	4980.78
	Short-term loans and advances	32.41
	Other current assets	68.23
	Total current assets	5165.32
	Total assets	7597.43
Disclosure of notes on assets and liabilities		Textual Information(1)

Text Block	
Textual Information(1)	1) Figures for the previous periods /year have been regrouped, restated and /or reclassified wherever considered necessary to make them comparable to the current periods /presentation. 2) The company has issued and allotted 42,84,000 equity shares of Rs.10 each at a premium of Rs 122 per share on 21/09/2023 through initial public offer as per section 52 of companies act, 2013, aggregating to Rs 5654.80 lakhs. The net issue expenses are Rs 765.80 lakhs has been adjusted against securities premium.

--

Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results		
Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2023	01-04-2023
Date of end of reporting period	30-09-2023	30-09-2023
Whether accounts are audited or unaudited	Unaudited	Unaudited
Nature of report standalone or consolidated	Standalone	Standalone
1 Segment Revenue		
(net sale/income from each segment should be disclosed)		
Total segment revenue		
Less: Inter segment revenue		
Revenue from operations		
2 Segment Result		
Profit (+) / Loss (-) before tax and interest from each segment		
Total Profit before tax		
i. Finance cost		
ii. Other unallocable expenditure net off unallocable income		
Profit before tax		
3 (Segment Asset - Segment Liabilities)		
Segment Asset		
Total Segment Assets		
Un-allocable Assets		
Net Segment Assets		
4 Segment Liabilities		
Segment Liabilities		
Total Segment Liabilities		
Un-allocable Liabilities		
Net Segment Liabilities		
Disclosure of notes on segments		

Cash flow statement - indirect		
	Particulars	6 months ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2023
B	Date of end of reporting period	30-09-2023
C	Whether results are audited or unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone
1 Statement of cash flows		
Cash flows from used in operating activities		
	Profit before extraordinary items and tax	28.71
2 Adjustments for reconcile profit (loss)		
Adjustments to profit (loss)		
	Adjustments for finance costs	31.87

	Adjustments for depreciation and amortisation expense	3.81
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for unrealised foreign exchange losses gains	-15.19
	Adjustments for dividend income	0
	Adjustments for share-based payments	0
	Other adjustments for which cash effects are investing or financing cash flow	0
	Other adjustments to reconcile profit (loss)	-78.64
	Other adjustments for non-cash items	-1.95
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	Total adjustments to profit (loss)	-60.1
3	Adjustments for working capital	
	Adjustments for decrease (increase) in inventories	0
	Adjustments for decrease (increase) in trade receivables	-21.47
	Adjustments for decrease (increase) in other current assets	-44.86
	Adjustments for increase (decrease) in trade payables	18.6
	Adjustments for increase (decrease) in other current liabilities	696.12
	Adjustments for provisions	2.94
	Total adjustments for working capital	651.33
	Total adjustments for reconcile profit (loss)	591.23
	Net cash flows from (used in) operations	619.94
	Dividends received	0
	Interest paid	0
	Interest received	0
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) operating activities before extraordinary items	619.94
	Proceeds from extraordinary items	0
	Payment for extraordinary items	0
	Net cash flows from (used in) operating activities	619.94
4	Cash flows from used in investing activities	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0.33
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of tangible assets	0
	Purchase of tangible assets	0.08
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Cash advances and loans made to other parties	1.41

	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	0
	Interest received	78.64
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	1.95
	Proceeds from government grants	0
	Net cash flows from (used in) investing activities before extraordinary items	78.77
	Proceeds from extraordinary items	0
	Payment for extraordinary items	0
	Net cash flows from (used in) investing activities	78.77
5	Cash flows from used in financing activities	
	Proceeds from issuing shares	5654.88
	Proceeds from issuing other equity instruments	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	0
	Repayments of borrowings	593.97
	Dividends paid	0
	Interest paid	0
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	-782.48
	Net cash flows from (used in) financing activities before extraordinary items	4278.43
	Proceeds from extraordinary items	0
	Payment for extraordinary items	0
	Net cash flows from (used in) financing activities	4278.43
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	4977.14
6	Effect of exchange rate changes on cash and cash equivalents	
	Effect of exchange rate changes on cash and cash equivalents	0
	Net increase (decrease) in cash and cash equivalents	4977.14
	Cash and cash equivalents cash flow statement at beginning of period	3.65
	Cash and cash equivalents cash flow statement at end of period	4980.79

Scrip code	
Scrip code	
NSE Symbol	UNIHEALTH
MSEI Symbol	NA
ISIN	INE0PRF01011
Name of company	Unihealth Consultancy Limited
Result Type	Main Format
Type of company	SME
Class of security	Equity
Date of start of financial year	01-04-2023
Date of end of financial year	31-03-2024
Date of board meeting when results were approved	08-11-2023
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	31-10-2023
Description of presentation currency	INR
Level of rounding used in financial results	Lakhs
Reporting Quarter	Half yearly
Nature of report standalone or consolidated	Consolidated
Whether results are audited or unaudited	Unaudited
Segment Reporting	Single segment
Description of single segment	Healthcare
Start date and time of board meeting	08-11-2023 11:00
End date and time of board meeting	08-11-2023 12:30
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable

Financial Results – Other than Bank			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2023	01-04-2023
B	Date of end of reporting period	30-09-2023	30-09-2023
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Revenue From Operations		
	Revenue from operations	2210.38	2210.38
	Other income	74.91	74.91
	Total Revenue	2285.29	2285.29
2	Expenses		
(a)	Cost of materials consumed	0	0

(b)	Purchases of stock-in-trade	484.02	484.02
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-13.83	-13.83
(d)	Employee benefit expense	360.72	360.72
(e)	Finance costs	153.49	153.49
(f)	Depreciation and amortisation expense	114.16	114.16
(g)	Other Expenses		
1	Miscellaneous	481.79	481.79
2	Locum and Specialist Payments	188.13	188.13
	Total other expenses	669.92	669.92
	Total expenses	1768.48	1768.48

Financial Results – Other than Bank			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2023	01-04-2023
B	Date of end of reporting period	30-09-2023	30-09-2023
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
3	Profit before exceptional and extraordinary items and tax	516.81	516.81
4	Exceptional items	0	0
5	Profit before extraordinary items and tax	516.81	516.81
6	Extraordinary items	0	0
7	Profit before tax	516.81	516.81
	Current tax	105.54	105.54
	Deferred tax	-18.48	-18.48
	Total tax expenses	87.06	87.06
9	Net Profit Loss for the period from continuing operations	429.75	429.75
10	Profit (loss) from discontinuing operations before tax	0	0
11	Tax expense of discontinuing operations	0	0
12	Net profit (loss) from discontinuing operation after tax	0	0
13	Profit (loss) for period before minority interest	429.75	429.75
14	Share of profit (loss) of associates	-4.39	-4.39
15	Profit (loss) of minority interest	1.04	1.04
16	Net profit (Loss) for the period	424.32	424.32

Financial Results – Other than Bank			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2023	01-04-2023

B	Date of end of reporting period	30-09-2023	30-09-2023
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
17	Details of equity share capital		
	Paid-up equity share capital	1540	1540
	Face value of equity share capital	10	10
17	Details of debt securities		
	Basic earnings (loss) per share from continuing and discontinued operations	3.15	3.15
20	Debt equity ratio		
21	Debt service coverage ratio	0.4	0.4
22	Interest service coverage ratio	4.37	4.37

Statement of Asset and Liabilities		
	Particulars	Half year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2023
	Date of end of reporting period	30-09-2023
	Whether results are audited or unaudited	Unaudited
	Nature of report standalone or consolidated	Consolidated
	Equity and liabilities	
1	Shareholders' funds	
	Share capital	1540
	Reserves and surplus	6520.32
	Money received against share warrants	
	Total shareholders' funds	8060.32
2	Share application money pending allotment	0
3	Deferred government grants	
4	Minority interest	-23.24
5	Non-current liabilities	
	Long-term borrowings	2784.2
	Deferred tax liabilities (net)	70.7
	Foreign currency monetary item translation difference liability account	
	Other long-term liabilities	
	Long-term provisions	0
	Total non-current liabilities	2854.9
6	Current liabilities	
	Short-term borrowings	81.72
	Trade Payables	
	(A) Total outstanding dues of micro enterprises and small enterprises	11.57
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	243.53
	Other current liabilities	1035.41
	Short-term provisions	182.5

	Total current liabilities	1554.73
	Total equity and liabilities	12446.71
	Assets	
1	Non-current assets	
(i)	Fixed assets	
	Tangible assets	2841.19
	Producing properties	0
	Intangible assets	760.75
	Preproducing properties	
	Tangible assets capital work-in-progress	
	Intangible assets under development or work-in-progress	
	Total fixed assets	3601.94

Statement of Asset and Liabilities		
Particulars		Half year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2023
Date of end of reporting period		30-09-2023
Whether results are audited or unaudited		Unaudited
Nature of report standalone or consolidated		Consolidated
(ii)	Non-current investments	24.59
(v)	Deferred tax assets (net)	
(vi)	Foreign currency monetary item translation difference asset account	
(vii)	Long-term loans and advances	685.81
(viii)	Other non-current assets	134.1
	Total non-current assets	4446.44
	Current assets	
	Current investments	0
	Inventories	167.97
	Trade receivables	2531.07
	Cash and cash equivalents	5112.65
	Bank balance other than cash and cash equivalents	0
	Short-term loans and advances	188.58
	Other current assets	
	Total current assets	8000.27
	Total assets	12446.71
	Disclosure of notes on assets and liabilities	Textual Information(1)

Text Block	
Textual Information(1)	1) Figures for the previous periods / year have been regrouped, restated and / or reclassified wherever considered necessary to make them comparable to the current periods /presentation. 2) The company has issued and allotted 42,84,000 equity shares of Rs.10 each at a premium if Rs.132 per share on 21/09/2023 through initial public offer as per section 52 of companies act, 2013, aggregating to Rs 5654.80 lakhs. The net issue expenses are Rs 765.80 lakhs has been adjusted against securities premium.

Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results		
Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2023	01-04-2023
Date of end of reporting period	30-09-2023	30-09-2023
Whether accounts are audited or unaudited	Unaudited	Unaudited
Nature of report standalone or consolidated	Consolidated	Consolidated
1 Segment Revenue		
(net sale/income from each segment should be disclosed)		
Total segment revenue		
Less: Inter segment revenue		
Revenue from operations		
2 Segment Result		
Profit (+) / Loss (-) before tax and interest from each segment		
Total Profit before tax		
i. Finance cost		
ii. Other unallocable expenditure net off unallocable income		
Profit before tax		
3 (Segment Asset - Segment Liabilities)		
Segment Asset		
Total Segment Assets		
Un-allocable Assets		
Net Segment Assets		
4 Segment Liabilities		
Segment Liabilities		
Total Segment Liabilities		
Un-allocable Liabilities		
Net Segment Liabilities		
Disclosure of notes on segments		

Cash flow statement - indirect		
	Particulars	6 months ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2023
B	Date of end of reporting period	30-09-2023
C	Whether results are audited or unaudited	Unaudited
D	Nature of report standalone or consolidated	Consolidated
1 Statement of cash flows		
Cash flows from used in operating activities		
	Profit before extraordinary items and tax	516.81
2 Adjustments for reconcile profit (loss)		
Adjustments to profit (loss)		

	Adjustments for finance costs	153.48
	Adjustments for depreciation and amortisation expense	114.16
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for unrealised foreign exchange losses gains	-30.12
	Adjustments for dividend income	0
	Adjustments for share-based payments	0
	Other adjustments for which cash effects are investing or financing cash flow	0
	Other adjustments to reconcile profit (loss)	-43.27
	Other adjustments for non-cash items	0
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	Total adjustments to profit (loss)	194.25
3	Adjustments for working capital	
	Adjustments for decrease (increase) in inventories	43.26
	Adjustments for decrease (increase) in trade receivables	208.31
	Adjustments for decrease (increase) in other current assets	-49.39
	Adjustments for increase (decrease) in trade payables	-40.73
	Adjustments for increase (decrease) in other current liabilities	463.2
	Adjustments for provisions	-2.04
	Total adjustments for working capital	622.61
	Total adjustments for reconcile profit (loss)	816.86
	Net cash flows from (used in) operations	1333.67
	Dividends received	0
	Interest paid	0
	Interest received	0
	Income taxes paid (refund)	87.06
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) operating activities before extraordinary items	1246.61
	Proceeds from extraordinary items	0
	Payment for extraordinary items	0
	Net cash flows from (used in) operating activities	1246.61
4	Cash flows from used in investing activities	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of tangible assets	0
	Purchase of tangible assets	13.92
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0

	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	0
	Interest received	42.03
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	-7.33
	Proceeds from government grants	0
	Net cash flows from (used in) investing activities before extraordinary items	20.78
	Proceeds from extraordinary items	0
	Payment for extraordinary items	0
	Net cash flows from (used in) investing activities	20.78
5	Cash flows from used in financing activities	
	Proceeds from issuing shares	5654.88
	Proceeds from issuing other equity instruments	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	0
	Repayments of borrowings	1060.75
	Dividends paid	0
	Interest paid	153.49
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	-735.68
	Net cash flows from (used in) financing activities before extraordinary items	3704.96
	Proceeds from extraordinary items	0
	Payment for extraordinary items	0
	Net cash flows from (used in) financing activities	3704.96
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	4972.35
6	Effect of exchange rate changes on cash and cash equivalents	
	Effect of exchange rate changes on cash and cash equivalents	-55.06
	Net increase (decrease) in cash and cash equivalents	4917.29
	Cash and cash equivalents cash flow statement at beginning of period	195.38
	Cash and cash equivalents cash flow statement at end of period	5112.67